Related references
Note: Only part of the references are listed.Finding very high lipoprotein(a): the need for routine assessment
Nick S. Nurmohamed et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period
Tigist Wodaje et al.
ATHEROSCLEROSIS (2022)
Sampling strategy, characteristics and representativeness of the InGef research database
M. Ludwig et al.
PUBLIC HEALTH (2022)
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg et al.
EUROPEAN HEART JOURNAL (2022)
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a) JACC Focus Seminar 2/4
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
Birgit Vogel et al.
LANCET (2021)
Lipoprotein(a) Testing Patterns in a Large Health System
Michelle Kelsey et al.
AMERICAN JOURNAL OF CARDIOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology
Wolfgang Hoffmann et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2019)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
Christian M. Madsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla et al.
ATHEROSCLEROSIS (2019)
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Rutger Verbeek et al.
EUROPEAN HEART JOURNAL (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome Analysis of the dal-Outcomes Randomized Clinical Trial
Gregory G. Schwartz et al.
JAMA CARDIOLOGY (2018)
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
Michael B. Boffa et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
Stephen Zewinger et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study
Nicolas Perrot et al.
ATHEROSCLEROSIS (2017)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Michael B. Boffa et al.
JOURNAL OF LIPID RESEARCH (2016)
Characteristics and external validity of the German Health Risk Institute (HRI) Database
Frank Andersohn et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Searching for a common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a)
Ilaria Romagnuolo et al.
FERTILITY AND STERILITY (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis
Alexander H. Nave et al.
ATHEROSCLEROSIS (2015)
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a) Prospective 15-Year Outcomes in the Bruneck Study
Peter Willeit et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans
Amir Ravandi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
The current status of lipoprotein (a) in pregnancy: A literature review
Angela E. Fanshawe et al.
JOURNAL OF CARDIOLOGY (2013)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Michael H. Davidson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage
CJ Glueck et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage -: Results of a multicentre case-control study
M Krause et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Lipoprotein (a) in pregnancy: A critical review of the literature
GTR Manten et al.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2005)
Lipoprotein(a) and coronary heart disease - Meta-analysis of prospective studies
J Danesh et al.
CIRCULATION (2000)
Share Paper
